Every Peptide Mentioned on the Diary of a CEO Podcast
In April 2025, Steven Bartlett's Diary of a CEO podcast featured Dr. Alex Tatem — a urologist and men's health clinician with twelve years of peptide research experience. The episode brought peptide therapy to one of the world's largest podcasting audiences and covered ten distinct compounds. Below is a full breakdown of every peptide named, what Dr. Tatem said about each, and what the research literature actually supports.
The Peptide Expert: Big Pharma Are Hiding This Powerful Peptide From You!
Guest: Dr. Alex Tatem · Host: Steven Bartlett · April 20, 2025
Dr. Alex Tatem is an internationally recognised urologist and men's health clinician who has spent twelve years studying peptide therapy. He runs a specialist men's health clinic and hosts his own YouTube channel focused on demystifying peptides for a general audience. His background in clinical medicine gives him a different vantage point from many peptide commentators — he discusses these compounds in the context of actual patient outcomes rather than purely theoretical biology. That said, this episode was produced for a mainstream audience, and some of the nuances around clinical trial status and regulatory complexity were necessarily compressed.
- The FDA quietly banned 19 peptides — and the current administration is reversing several of those bans. Dr. Tatem walked through the policy history and what it means for researcher access.
- Big Pharma's financial disincentive to develop unpatentable peptides was a central thread — explaining why many highly effective compounds remain in a research-only grey zone.
- Peptides cannot independently build significant muscle mass — they support biological processes but are not a substitute for training and nutrition.
- Quality control in the research peptide market is the most significant practical risk — endotoxin contamination and inaccurate dosing from unregulated suppliers are real concerns.
- GLP-1 drugs like semaglutide and tirzepatide are themselves peptides — and their approval demonstrates that when pharma can patent a peptide, it moves through regulation quickly.
The Peptides — What Was Said & What the Research Shows
Each compound is summarised with what Dr. Tatem specifically said, an objective overview of the research, and a direct link to the compound at Base Peptides.
BPC-157
What Dr. Tatem Said
Dr. Tatem personally stated he would have used BPC-157 alongside TB-500 to accelerate recovery from a recurring shoulder injury. He highlighted its gut healing properties — noting it is particularly effective in ulcerative colitis — and explained that BPC-157 is unusual in that there is a form tolerated in the gut, making oral administration a valid option for GI applications specifically.
What It Is
A synthetic 15-amino-acid peptide fragment derived from a protein found in human gastric juice. BPC-157 has been studied extensively in animal models for tendon-to-bone healing, muscle tear recovery, ligament repair, and gut barrier restoration. It is one of the most widely discussed recovery peptides in the research community.
Key Research Areas
- Accelerated tendon and ligament healing in multiple rodent models
- Gut mucosal repair — shown to reduce colitis severity in animal IBD studies
- Modulation of the nitric oxide system for improved blood flow to injury sites
- Neuroprotection and systemic stabilization effects via dopamine/serotonin pathways
Research context: No completed human clinical trials as of 2025. All efficacy data for human applications is extrapolated from animal studies and practitioner anecdotal reports. Research compound only.
TB-500
What Dr. Tatem Said
Dr. Tatem described TB-500 as the 'brother' to BPC-157. He explained that while BPC-157 works at the repair site, TB-500 improves blood flow to the injured area — effectively 'sending the soldiers' that rebuild the tissue matrix damaged by a tear or injury. He also used it as an opportunity to explain why these peptides must be injected: if you drank TB-500, your body would break it down like any protein in food, so injection is necessary to preserve its biological activity.
What It Is
A synthetic fragment of Thymosin Beta-4, a protein present in virtually every nucleated cell. TB-500 promotes healing through actin regulation, angiogenesis (new blood vessel formation), and systemic cell migration to injury sites. Because it distributes systemically, it reaches injuries regardless of where the injection is given.
Key Research Areas
- Muscle fiber repair following tears and high-load training
- Cardiac tissue protection following ischemic injury — studied in rodent and porcine models
- Wound healing including chronic non-healing wounds
- Neurological tissue repair and remyelination research
Research context: Animal studies raise a concern about potential acceleration of dormant tumor growth in certain contexts. No completed human clinical trials for anabolic or recovery applications.
Semaglutide (GLP-1)
What Dr. Tatem Said
GLP-1 agonists featured prominently in the episode as the most mainstream example of peptide therapy that has gone from research compound to blockbuster drug. Dr. Tatem displayed a Mounjaro (tirzepatide) injection pen on screen to illustrate how far peptide medicine has entered clinical practice. The episode covered the future of muscle retention on GLP-1s — a critical emerging concern — and how these peptides can transform insulin sensitivity.
What It Is
Semaglutide is a GLP-1 receptor agonist that mimics the gut hormone glucagon-like peptide-1. It suppresses appetite, slows gastric emptying, and improves pancreatic insulin response. It is the active ingredient in Ozempic (diabetes) and Wegovy (obesity) and is one of the most prescribed drugs globally.
Key Research Areas
- Average 15% body weight reduction in STEP trials over 68 weeks
- Significant cardiovascular risk reduction in SELECT trial
- HbA1c reduction in type 2 diabetes management
- Emerging research on addiction, dementia, and NASH treatment
Research context: Nausea and GI side effects common. Muscle mass loss is a documented concern with GLP-1-driven weight loss — resistance training and adequate protein are strongly advised. Compounded versions raise purity and dosing accuracy concerns.
Tirzepatide (Mounjaro)
What Dr. Tatem Said
Dr. Tatem held up a Mounjaro pen — the brand-name tirzepatide product — during the episode to illustrate the mainstreaming of peptide therapy. Tirzepatide represents a next step beyond semaglutide: it activates both GLP-1 and GIP receptors simultaneously, producing greater weight loss outcomes than semaglutide in head-to-head trials.
What It Is
Tirzepatide is a dual GIP/GLP-1 receptor agonist — the first of its class. By activating both receptors, it achieves a more profound metabolic effect than GLP-1 monotherapy, including greater insulin sensitization and fat mass reduction. It is FDA-approved as Mounjaro (diabetes) and Zepbound (obesity).
Key Research Areas
- SURMOUNT-1 trial: average 20.9% body weight reduction at highest dose over 72 weeks
- Superior weight loss to semaglutide in SURPASS-6 head-to-head
- Significant improvements in waist circumference, lipid profile, and blood pressure
- Ongoing research in NASH, heart failure with preserved ejection fraction, and sleep apnea
Research context: Similar side effect profile to semaglutide. Muscle mass loss with rapid fat loss is a concern. Cost and access issues drive compounded market demand. Purity verification of research-grade product is essential.
GHK-Cu (Copper Peptide)
What Dr. Tatem Said
Dr. Tatem mentioned GHK-Cu in the context of skin quality improvement — one of the more accessible and visible applications of peptide therapy. It was cited as an example of a peptide with a well-characterized mechanism and established cosmetic research backing.
What It Is
GHK-Cu is a naturally occurring copper peptide found in human plasma. It stimulates collagen and elastin synthesis, promotes wound healing, reduces inflammation, and modulates gene expression across thousands of aging-related genes. It is used both topically and via injection.
Key Research Areas
- Collagen I, III, and VI upregulation in fibroblast studies
- Clinically demonstrated improvement in skin laxity and fine lines (Leyden et al.)
- Alteration of 4,000+ gene expressions toward a more youthful pattern (Pickart & Margolina 2012)
- Hair follicle stimulation research for androgenic alopecia
Research context: Most compelling skin data comes from topical formulation studies, not injectable research. Injectable forms are less well-characterized for systemic effects.
KPV
What Dr. Tatem Said
KPV was mentioned in the episode in the context of angiogenesis and tissue repair — part of the broader discussion of how different peptides address different aspects of the healing cascade. It was presented as one of several peptides with a specific mechanistic role rather than broad-spectrum healing.
What It Is
KPV is a tripeptide (Lys-Pro-Val) derived from the C-terminus of alpha-MSH (alpha-melanocyte-stimulating hormone). It is a potent anti-inflammatory that works primarily through the melanocortin receptors MC1R and MC3R, reducing NF-κB activation and inflammatory cytokine output. It also promotes angiogenesis and wound repair.
Key Research Areas
- Anti-inflammatory activity in gut mucosa — IBD and colitis animal models
- Wound healing and angiogenesis promotion
- Skin inflammation reduction — research in psoriasis and contact dermatitis models
- Gut barrier protection from pathogen-induced permeability
Research context: Research is primarily preclinical. Limited human data available. Should be distinguished from alpha-MSH itself due to structural differences and receptor subtype selectivity.
MOTS-C
What Dr. Tatem Said
MOTS-C was one of the more striking peptides discussed in the episode, described by patients as 'exercise in a vial.' Dr. Tatem explained that it improves VO2 max and exercise tolerance by upregulating the energy pathway — essentially making more ATP available — giving users significantly enhanced physical capacity and endurance.
What It Is
MOTS-C is a mitochondria-derived peptide encoded within the mitochondrial genome's 12S rRNA region. It regulates metabolic homeostasis by activating AMPK and improving mitochondrial function. Circulating levels decline with age, and it has been extensively studied for exercise mimicry, insulin sensitization, and longevity research.
Key Research Areas
- AMPK activation mimicking exercise-like metabolic adaptations
- Improved insulin sensitivity independent of caloric restriction in animal models
- Age-related muscle function preservation in rodent aging studies
- Exercise performance enhancement — VO2 max improvements documented in primate research
Research context: Human clinical data is emerging but limited. Optimal human dosing not yet established. Most robust evidence is from rodent and primate studies. Long-term effects unknown.
DSIP (Delta Sleep-Inducing Peptide)
What Dr. Tatem Said
DSIP was discussed in the context of sleep quality improvement — a segment of the episode Dr. Tatem described as among the highest-impact applications of peptide therapy given how central sleep is to recovery, cognitive function, and longevity. It was grouped with Epitalon as peptides that affect the sleep-cognition axis.
What It Is
Delta Sleep-Inducing Peptide (DSIP) is a neuropeptide first isolated in 1974 from rabbit blood during delta-wave (deep) sleep. It promotes slow-wave sleep, reduces cortisol, and demonstrates anxiolytic properties. It also modulates pituitary hormone release, including GH, which is predominantly secreted during deep sleep.
Key Research Areas
- Promotion of delta-wave (slow-wave) sleep stages in human and animal studies
- Cortisol reduction and stress response modulation
- Withdrawal symptom management in alcohol and opioid dependence research
- Antioxidant and cardioprotective effects in peripheral tissue
Research context: Mechanism of action is not fully characterized. Human research is dated (primarily 1980s–90s) and studies are small. No large-scale modern clinical trials.
Epitalon
What Dr. Tatem Said
Epitalon was mentioned alongside DSIP as a peptide affecting cognitive function and sleep quality — and more broadly as one of the leading longevity peptides. It was described in the context of the peptides Dr. Tatem considers for circadian rhythm regulation and cellular aging.
What It Is
Epitalon (also spelled Epithalon) is a synthetic tetrapeptide (Ala-Glu-Asp-Gly) that activates telomerase — the enzyme responsible for maintaining telomere length. It was developed by Vladimir Khavinson's group at the St. Petersburg Institute of Bioregulation and Gerontology and is one of the most studied longevity peptides in the Russian research tradition.
Key Research Areas
- Telomerase activation and telomere lengthening in human cell cultures
- Circadian rhythm normalization via melatonin regulation in the pineal gland
- Reduced incidence of age-related pathology in long-term rodent studies
- Antioxidant and DNA repair activity in aged cell models
Research context: Long-term human clinical data is limited to Russian studies, which vary in methodological rigor by Western standards. No FDA-approved indication. Regulatory status varies by country.
Semax
What Dr. Tatem Said
Semax was highlighted as one of the peptides returning to legal availability following FDA policy changes — specifically intranasal Semax, which Dr. Tatem noted was originally developed in Russia and showed that patients recovering from traumatic brain injuries tended to bounce back faster. He cited it as an example of clinically relevant peptides that had been swept up in the FDA's broad peptide ban before RFK Jr.'s policy reversals.
What It Is
Semax is a heptapeptide (7 amino acids) based on a fragment of ACTH (adrenocorticotropic hormone). It was developed in Russia in the 1980s and is approved for clinical use there for stroke recovery, TBI, and cognitive impairment. It significantly upregulates BDNF (brain-derived neurotrophic factor) and provides neuroprotective effects via multiple mechanisms.
Key Research Areas
- BDNF upregulation — one of the most consistent and significant nootropic mechanisms
- Stroke and TBI neurological recovery in human clinical trials (Russian approval basis)
- Cognitive enhancement in memory, focus, and processing speed in healthy adults
- Neuroprotection against ischemic damage in animal models
Research context: Most human clinical data is from Russian research, which may not meet Western RCT standards. Not FDA-approved. Regulatory status in the US remains complex — was among banned peptides under recent FDA action, with partial reversal under current policy review.
Why This Episode Reached Such a Wide Audience
Steven Bartlett's podcast consistently reaches tens of millions of listeners globally, and a peptide episode featuring a clinician — rather than a biohacker or supplement entrepreneur — gave the topic a credibility it hadn't previously had in mainstream media. For many listeners, this was their first introduction to the concept that some of the most effective treatments in preventive and performance medicine exist in a regulatory grey zone driven more by patent economics than safety evidence.
Dr. Tatem was careful throughout to frame these compounds as research tools — not over-the-counter supplements. The distinction matters: the peptides discussed above range from those with decades of published research (BPC-157, Epitalon, Semax) to FDA-approved blockbusters derived from the same peptide pharmacology (semaglutide, tirzepatide) to emerging mitochondria-derived compounds with a growing but still limited human evidence base (MOTS-C, DSIP).
If this episode prompted your interest, the best next step is to read the research profile for each compound you're considering, understand the current regulatory context in your country, and consult a physician who is familiar with peptide therapy before making any decisions about personal use.
Other Articles
Calculator
Calculate exact reconstitution volumes and insulin unit doses for any peptide protocol.
Open Calculator →